GB814491A - Lipid mobiliser - Google Patents
Lipid mobiliserInfo
- Publication number
- GB814491A GB814491A GB38506/56A GB3850656A GB814491A GB 814491 A GB814491 A GB 814491A GB 38506/56 A GB38506/56 A GB 38506/56A GB 3850656 A GB3850656 A GB 3850656A GB 814491 A GB814491 A GB 814491A
- Authority
- GB
- United Kingdom
- Prior art keywords
- lipid
- mobilizer
- specified
- free
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A lipid mobilizer may be obtained by dialysing the plasma of stressed mammals and freeze drying the dialysate. Specified nammals are rat, dog, man and preferably horse. Specified stresses are subjection to sub-normal temperature above 0 DEG C., administration of a convulsant drug such as diisopropylfluorophosphate or cholic acid, injection of protamine, anti-kidney serum or preferably cortisone. The lipid mobilizer may be dissolved in pyrogen-free aqueous medium for parenteral administration. The lipid mobilizer has the property when injected into animals of producing hyperlipemia, hyperphagia and depleting fat deposits in the body. It is a non-protein solid, freely soluble in water and physiological salt solution, less soluble in methanol and insoluble in 95 per cent ethanol or acetone, non-extractable by ether from acid or alkaline aqueous solutions, dialysable through semi-permeable membranes against water, comprising a low molecular weight polypeptide as the active ingredient, free of steroids and giving a positive ninhydrin reaction.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US814491XA | 1956-01-17 | 1956-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB814491A true GB814491A (en) | 1959-06-03 |
Family
ID=22164234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB38506/56A Expired GB814491A (en) | 1956-01-17 | 1956-12-18 | Lipid mobiliser |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB814491A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758724A1 (en) * | 1997-01-24 | 1998-07-31 | Javenech | Controlling cellulite and fat deposition |
| US9863699B2 (en) | 2014-06-09 | 2018-01-09 | Terumo Bct, Inc. | Lyophilization |
| US10793327B2 (en) | 2017-10-09 | 2020-10-06 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
-
1956
- 1956-12-18 GB GB38506/56A patent/GB814491A/en not_active Expired
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758724A1 (en) * | 1997-01-24 | 1998-07-31 | Javenech | Controlling cellulite and fat deposition |
| US9863699B2 (en) | 2014-06-09 | 2018-01-09 | Terumo Bct, Inc. | Lyophilization |
| US10539367B2 (en) | 2014-06-09 | 2020-01-21 | Terumo Bct, Inc. | Lyophilization |
| US10969171B2 (en) | 2014-06-09 | 2021-04-06 | Terumo Bct, Inc. | Lyophilization |
| US10976105B2 (en) | 2014-06-09 | 2021-04-13 | Terumo Bct, Inc. | Lyophilization |
| US11067336B2 (en) | 2014-06-09 | 2021-07-20 | Terumo Bct, Inc. | Lyophilization |
| US11137206B2 (en) | 2014-06-09 | 2021-10-05 | Terumo Bct, Inc. | Lyophilization |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| US10793327B2 (en) | 2017-10-09 | 2020-10-06 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11994343B2 (en) | 2019-03-14 | 2024-05-28 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Permin | Properties of the fibrinokinase-fibrinolysin system | |
| Feldberg et al. | The formation of lysocithin and of a muscle-stimulating substance by snake venoms | |
| Fink et al. | PLASMA PROTEIN METABOLISM—NORMAL AND ASSOCIATED WITH SHOCK: OBSERVATIONS USING PROTEIN LABELED BY HEAVY NITROGEN IN LYSINE | |
| BERCU et al. | Antidiuretic action of the urine of patients in cardiac failure | |
| Lorenz et al. | Histamine in the pig: determination, distribution, release and pharmacological actions | |
| Nasset | Enterocrinin, a hormone which excites the glands of the small intestine | |
| GB814491A (en) | Lipid mobiliser | |
| US3200110A (en) | Process for the preparation of laminarin sulfates | |
| FENCL et al. | Effect of RNA from estradiol-treated immature rats on protein synthesis in immature uteri | |
| Menkin | Studies on inflammation: Xvi. On the formation of a chemotactic substance by enzymatic action | |
| Davies et al. | Observations on the preparation, properties and source of the parathyroid hormone. Part I | |
| Walser et al. | 522 The effect of diuresis and diuretics upon the renal tubular transport of alkaline earth | |
| SCHNITKER et al. | Presence of digitalis in body fluids of digitalized patients | |
| GB721312A (en) | Improvements in or relating to the formation of fibrous protein from solutions of collagen | |
| ES358119A1 (en) | Cosmetic therapeutic preparations containing animal organ extracts | |
| Houssay et al. | Renin in Experimental Hypertension | |
| Nadal et al. | Inhibition of rat hepatocyte multiplication by serum and liver factors: Physiological development and experimental induction | |
| Gagliardino et al. | Relationship between differential responsiveness of pancreatic β cells and the circadian variation of serum immunoreactive insulin levels | |
| Ovcharov et al. | Anti-inflammatory effects of apamin | |
| Abel et al. | Evaluation of the hormone of the infundibulum of the pituitary gland in terms of histamine, with experiments on the action of repeated injections of the hormone on the blood pressure | |
| Cullumbine | Leukotaxine and histamine | |
| Bornstein et al. | Mechanism of the diabetogenic action of growth hormone I. Effect of polypeptides derived from growth hormone on glycolysis in muscle | |
| Agar et al. | The inhibition of the intestinal absorption of an amino acid by chlortetracycline | |
| GB974910A (en) | Polypeptide growth promoting agent for animals | |
| Despopoulos | 521 Renal transport of organic anions: a unifying hypothesis |